Noopept

evidence score

nootropic

Gray Market

396 studies

GVS-111N-phenylacetyl-L-prolylglycine ethyl esteromberacetam

Noopept is a synthetic dipeptide originally developed in Russia as a peptide mimic of the C-terminal fragment of piracetam. Rapidly crosses the blood-brain barrier and converts to cycloprolylglycine, an endogenous neuropeptide. Among the most potent nootropics by mass — effective at 10–30mg vs piracetam's 1,600–4,800mg. Stimulates NGF and BDNF expression; described as an anxiolytic-nootropic with memory-consolidating properties. Extensively studied in Russian pre-clinical and limited clinical literature (primarily post-stroke and traumatic brain injury). Gray-market legal status in the US and most Western countries. Sublingual administration significantly increases bioavailability.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

No formal trials

Research Sync

Feb 19, 2026

Dosing

Typical

20 mg

10 mgRange30 mg

FrequencyOnce or twice daily (sublingual preferred for bioavailability)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~5–10 minutes (rapid hydrolysis); cycloprolylglycine metabolite is active

Onset15–30 minutes

Duration3–6 hours

Routes

oral

sublingual

Evidence Score

Level B — Moderate

396 studies indexed · 2 meta-analyses

Scoring Factors

Volume(40%)~52/100

Quality(30%)~44/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Noopept is currently categorized as a nootropic compound.

Evidence is moderate (67/100): promising signal from 396 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Dipeptide nootropic; metabolizes to cycloprolylglycine; upregulates NGF and BDNF; modulates AMPA and NMDA receptors; anxiolytic-nootropic profile

Practical Context

Strongest current signals

Level A: Meta-Analysis of Randomized Controlled Trials on IV Thrombolysis in Patients With Minor Acute Ischemic Stroke.
Level C: Artificial Intelligence's Potential in Zoo Animal Welfare.
Level C: Apolipoproteins in ischemic stroke progression and recovery: Key molecular mechanisms and therapeutic potential.